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Background/aim: This study evaluated the treatment procedures for chemotherapy (CT)-induced persistent azoospermia and their
outcomes from a different perspective.
Materials and methods: In 63 patients (mean age: 30.16 ± 4.91 years) who had undergone CT 11 ± 5 years earlier, the semen volume,
gonadotropins level, FSH level, genetics, micro-testicular sperm extraction (m-TESE) result, sperm DNA fragmentation index (SDFI),
semen reactive oxidative stress (ROS) rate, duration of embryonic development, and pregnancy and baby take-home rates were
examined. The correlations between the ROS rates and the SDFIs, m-TESE results, sperm motility, pathology scores, time-lapses, and
baby take-home rates were evaluated.
Results: The semen volumes were 3.5 ± 1.1/ml. The FSH level following CT was 17.87 ± 5.80 mIU/ml. A sperm rate of 34.9% was found
from the m-TESE result. The mean SDFI and ROS rate were 4 (<15–30>) and 1.29 ± 0.51, respectively. The time-lapse was calculated as
5h. Pregnancy and live birth were achieved at 20.63% and 12.7%, respectively. In the patients with a low ROS (≤1.42) and SDFI (≤15), the
m-TESE success rate was high, the FSH value was low, the pathological score and fertilization rate were elevated, the embryonic cleavage
period was normal, and the pregnancy and baby take-home rates were high.
Conclusion: The sperms may be detected using m-TESE in patients who develop persistent azoospermia associated with CT due to
different oncological diagnoses. Our study revealed that a low FSH value and normal ejaculatory ROS rates are positive predictive
factors of sperm detection before m-TESE. The motility of the sperms detected after m-TESE and normal SDFI rates were found to be
positive predictive criteria of high fertilization, good embryonic cleavage, pregnancy, and live birth.
Key words : Azoospermia, chemotherapy, m-TESE, SDFI, ROS, male, infertility

1. Introduction
After cardiovascular diseases, cancer is one of the most
commonly diagnosed diseases worldwide. According to
the World Health Organization (WHO), 9.6 million people
died due to cancer in 2018 [1]. Early diagnosis, newgeneration chemotherapy (CT) agents, and modifications
in treatment protocols have had positive impacts on life
expectancy [2]. However, these treatments are known to
harm the spermatogenetic activities of the testes and many
other organs [2].
Approximately 7% of men worldwide are infertile
[3,4]. Primary infertility refers to the failure of spouses
to achieve a clinical pregnancy despite 12 months of

unprotected sexual intercourse. Secondary infertility refers
to the failure of spouses to have a second child. Men are
solely responsible for 20%–30% of primary infertility cases
and for about 50% of primary and secondary infertility
cases combined [3,4]. Male infertility has many causes,
such as genetic factors, varicocele, hormonal dysfunctions,
obstructive causes, testicular trauma, undescended testis,
unhealed testicular infections, mumps, and cancer [3,4].
Reactive oxygen species (ROS) are significant factors
of male infertility because they decrease sperm production
and damage the produced sperm [3,4]. CT and radiation
therapy or radiotherapy (RT) lead to these outcomes
because they generate ROS in the short and long terms [4].
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They severely damage the sperm DNA, mitochondria, and
nuclei [4] and are thus transiently or even permanently
toxic for sperms and sperm stem cells [5,6]. Sperm stem
cells are fast-growing cells that are particularly highly
sensitive to CT. They begin to die within two to three
months after CT. Consequently, permanent azoospermia
may develop [5, 6]. In our clinical practice, we have
measured the damage in the sperms and semen of our
azoospermia patients through their ROS and sperm DNA
fragmentation index (SDFI) rates [4]. There are two ways
to preserve fertility in these patients: by freezing sperms or
testicular tissues before treatment (called sperm freezing
or sperm cryopreservation) or by retrieving sperms
via micro-testicular sperm extraction (m-TESE) after
treatment. Unfortunately, it may not be possible to retrieve
sperms with m-TESE following CT [7]. Therefore, sperm
cryopreservation is the safest method [7]. In this study, the
clinical outcomes of CT-induced persistent azoospermia
patients were evaluated, and the laboratory results of
treatment procedures, including the surgical, fertilization,
pregnancy, and live birth rates, were assessed in terms of
their correlation with the patients’ measured ROS and
SDFI rates.
2. Materials and methods
The files were reviewed retrospectively upon the approval
of the ethics committee of the school of medicine of
Necmettin Erbakan University, through its decision no.
2019/2107 adopted in its Session 1 on 01/10/2019. A total
of 63 patients had been screened between 2008 and 2018.
Their semen analyses were checked twice via pellet control
(WHO, 2010). Their follicle-stimulating hormone (FSH),
luteinizing hormone (LH), total testosterone (TT), and
prolactin (PRL) were checked. Their urine and ejaculate
were assessed microbiologically. The FSH values before CT
and after m-TESE were recorded. The karyotypes and Y
chromosome microdeletions were checked. The SDFI rates
were detected via (terminal deoxynucleotidyl transferase
dUTP nick end labeling) TUNEL assay. SDFI values of
<15, 15–30, and >30 were regarded as normal, suspicious,
and positive, respectively [8]. Between 2016 and 2018,
the ROS levels in fresh neat semen of the patients were
measured using a chemiluminescence assay in a singletube luminometer (MiOXSYS® system) [9]. The ROS value
of <1.42 mV/106 sperms/mL in the semen was regarded as
normal [9]. The patients underwent m-TESE once or twice.
M-TESE was applied with a surgical light microscope with
a 25 × 13.5-fold magnification power under anesthesia.
The testis tissue pathologies were evaluated using the
Johnsen score (footnote, Table 1, cut-off score of ≥4 in the
presence of sperms). The embryos were followed up with
a time-lapse (Unisense Fertilitech®) [10]. The sperm tissues
and embryos were preserved after intracytoplasmic sperm

injection (ICSI). The pregnancy and baby take-home rates
were followed up. The m-TESE and FSH rates, pathologies,
fertilized oocyte counts, pregnancy rates, sperm motility/
nonmotility rates, and embryonic cleavage period under
a time-lapse were evaluated individually according to
their ROS positivity/negativity and SDFI <15/>15 levels
(suspicious + positive group) to identify whether they
were a criterion. We excluded other factors that could
affect the ROS and SDFI rates, and we tried to demonstrate
the impact of CT on spermatogenetic activity regardless of
whether it was subjective.
2.1. Statistical analysis
In the descriptive data statistics, the values of mean,
standard deviation, median lowest, highest, frequency,
and ratios were utilized. The distribution of the variables
was measured by the Kolmogorov Smirnov test. The
independent samples T-test and Mann-Whitney U test
were used in the analysis of quantitative independent
data. The Wilcoxon test was utilized in the analysis of
dependent quantitative data. The chi-square test, or in case
of failure to fulfill the necessary conditions for the chisquare test, the Fisher’s exact test was used in the analysis
of independent quantitative data. The SPSS 22.0 program
was utilized in the analyses.
3. Results
The mean number of years following CT was 9.9 (6–16
y). The patients who were admitted to the hospital for
infertility treatment had not been receiving any tumorrelated treatment. Thirteen patients had undergone bone
marrow transplantation for acute lymphocytic leukemia
(ALL), three patients; for acute myeloid leukemia (AML),
three patients; for non-Hodgkin’s lymphoma (NHL), four
patients; and for Hodgkin’s lymphoma (HL), one patient.
While testicular cancers were observed most frequently
(in 32/63 patients (50.7%)), chronic myeloid leukemia
(CML), Ewing sarcoma, and Wilms’ tumor were detected
less frequently (in 1/63 patient (1.6%) for each condition)
(Table 1). The examinations of the patients revealed that
eight of them had undergone varicocelectomy before
CT, and seven had varicocelectomy following CT. BEP
(Bleomycin Etoposide Cisplatin) was administered for
testicular volumes at 3-week intervals with a median
of 3 cycles, while radiotherapy was administered to 6
patients with seminoma. The ALL patients received one
cure each of vincristine, steroid, L-asparaginase, and
cyclophosphamide, and the AML patients received three
cures each of daunorubicin, idarubicin, and mitoxantrone
(on three consecutive days). The CML patient received one
cure each of splenic irradiation, busulfan, hydroxyurea,
interferon alfa, imatinib, and dasatinib. The HL patient
received three cures of MOPP (mechlorethamine
hydrochloride,
vincristine
sulfate,
procarbazine
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Table 1. Demographic characteristics: oncological diagnoses, body mass index (BMI/kg).
Min-max

Median

Patients/years

21–42

30

Spouse’s age/years

18–36

25

Duration of marriage/years

0.80–12.60

3.4

Oncological diagnoses

Number

%

BMI/kg min-max

Seminoma

24

38

14.1–22.3

Nonseminoma

8

12.7

14.2–23.2

ALL

8

12.7

10.7–24.1

AML

3

4.8

13.3–17.9

CML

1

1.6

-

Hodgkin’s lymphoma

4

6.3

13.77–21.57

Non-Hodgkin’s lymphoma

8

12.7

15.66–29.46

Rhabdomyosarcoma

2

3.2

-

Soft tissue Ewing sarcoma

1

1.6

-

Osteosarcoma

3

4.8

11.5–28.1

Wilms tumor

1

1.6

23.4

Smoking (-) rate

47

74.6

-

SSPS 22.0
ALL: Acute lymphoblastic leukemia. AML: Acute myelocytic leukemia. CML: Chronic
myelocytic leukemia. Johnsen score of testicular biopsies score morphological base:
1 Tubular sclerosis, 2 Sertoli cells only, 3 Spermatogonia only, 4 Arrest at primary
spermatocyte, no, spermatids, 5 Many spermatocytes, no spermatids, 6 No late
spermatids, arrest at spermatid stage, 7 No late spermatids, but many early spermatids,
8 Few late spermatids 9 Many late spermatids, disorganized tubular epithelium, 10 Full
spermatogenesis

hydrochloride, and prednisone) while RT was applied
to the lesion areas. The NHL patients received R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine,
and prednisolone) and then underwent head neck RT.
The rhabdomyosarcoma patient received vincristine and
actinomycin and then underwent RT. The Ewing sarcoma
patient received vincristine, adriamycin, actinomycin-D,
and cyclophosphamide and then underwent RT. The
osteosarcoma patient received adriamycin, methotrexate,
cisplatin, ifosfamide + mesna, and etoposide and then
underwent RT. The patient with Wilms tumor received
actinomycin D, vincristine, and doxorubicin and then
underwent RT. The CT and RT protocols of nine patients
with testicular tumors were renewed, and four patients
underwent retroperitoneal lymphatic gland dissection.
In three NHL patients and two HL patients, the CT/RT
cures were repeated after their cancer returned following
remission. Types 1 and 2 diabetes mellitus were diagnosed
in two seminoma patients, three nonseminoma patients,
one HL patient, and two NHL patients. No patient was
treated for spermatogenetic activation before and during
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m-TESE. Hypertension was detected in one HL and three
NHL patients. All the patients applied while they were
experiencing persistent azoospermia. None of their sperms
had been frozen previously. They reported that they had
not been informed regarding this matter. All the patients
had the karyotype 46XY. Partial azoospermia factor C
(AZFc) deletion was identified in one patient. The semen
analyses revealed pellet negativity with azoospermia with
an average volume of 3.3 cc (3.26 ± 1.13). Sperms were
detected at a rate of 34.9% in a total of 22/63 patients in
their first and second m-TESE procedures (Table 2). While
the sperm retrieval rate with m-TESE was highest in 14/32
(43.7%) of the patients with testicular cancer, sperms were
detected in 2/8 (25%) of the ALL patients, in 1/3 (33%) of
the patients with osteosarcoma, in 1/3 (33%) of the AML
patients, in 1/4 (25%) of the HL patients, and in 3/8 (37.5%)
of the NHL patients. No sperm was found in the patients
with Wilms’ tumor, soft tissue Ewing sarcoma, CML, and
rhabdomyosarcoma. The average m-TESE duration was
102 min (25–161 min). Pregnancy was achieved after the
first and second ICSI at a rate of 59%. The pregnant women’s
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Table 2. Number and success rate of micro-testicular sperm extraction, semen reactive oxidative
stress, testicular pathological results, DNA fragmentation of sperms in the testicular tissue,
pregnancy rates, fertilized oocyte count, and embryo separation period at time-lapse.
Number

Means/results

%

m-TESE (+) total results

63

22(+)/41(-)

34.9

m-TESE 1st

48

16(+)/32(-)

-

m-TESE 2

15

6(+)/9(-)

-

m-TESE 1st motile(m)/nonmotile(im)

22

13(m)/9(im)

-

m-TESE (+) Jhs score

19

6(4–8)

-

m-TESE (-) Jhs score

44

2(1–6)

-

m-TESE time/min.

25-161

102(100.59 ± 21.1)

-

ICSI-total pregnancy

13

13/63

20.63

ICSI 1 (m-TESE 1 )

16

9(+)/63

14.28

ICSI 2nd (m-TESE 1st and 2nd)

13

4(+)/63

6.34

ICSI total take of baby

8

8/63

12.7

ICSI 1 (m-TESE 1 )

16

5(+)/63

7.93

ICSI 2th (m-TESE 1st and 2nd)

13

3(+)/63

4.76

Number of children before CT

31

1(1–3)

-

Number of oocytes expose to ICSI

168

69 (fertilization)

41

Total time-lapse divided time/h

168

5(4.4–14)

-

SDFI rate in the m-TESE tissue

17

4(15–30)

-

ROS test/mV/10 sperm/mL

0.35-2.56

-

-

nd

st

st

st

st

6

SSPS 22.0
m-TESE: Micro-testicular sperm extraction, CT: Chemotherapy, Jhs: Johnsen’s testicular
pathologic score, ICSI: Intracytoplasmic sperm injection, Time-Lapse: Embryoscope®, SDFI:
Sperm DNA fragmentation index. Motile/immotile sperm: (m)/(im).

baby take-home rate was 12.7%. The pathological mean
Johnsen (JHS) score in the m-TESE positive (+) group
was 6, and the mean rate was 2 in the m-TESE negative
(-) group. The m-TESE was repeated in 15 patients whose
first m-TESE (-) resulted in the detection of sperms in six
patients.
Nonmotile sperms were detected in two patients in the
repeat m-TESE during their quarterly/biannual followups. However, no embryo development was seen in one
patient after ICSI, and no pregnancy was achieved in the
other patient.
In the m-TESE (+) group, the SDFI was <15 in 13
patients, ≥15 in two patients, and >30 in two patients. The
ROS test resulted in a normal rate of <1.42 in 12 patients,
and in a high rate of ≥1.42 in six patients. Embryos were
followed up with a time-lapse after ICSI. In practice, a
blastomere separation period of <6 h is regarded as normal
[9]. While the mean blastomere separation period in all
the patients was 5 h, the mean separation period in the
13 patients in the pregnancy group was >11 h on average
(Table 2).

3.1. Statistical results in the m-TESE (+) and (-) groups
The ages of the patients and their spouses and in the
marriage durations; smoking rates; m-TESE periods; FSH,
LH, TT, and PRL values before CT; and m-TESE and ROS
test results did not differ significantly (p > 0.05) between the
m-TESE (-) and m-TESE (+) groups. The FSH value before
the m-TESE increased significantly (p < 0.05) after CT in
the m-TESE (-) group. Likewise, the FSH value before the
m-TESE increased significantly (p < 0.05) after CT in the
m-TESE (+) group. The semen volumes in the m-TESE (+)
group were significantly higher (p < 0.05) than those in
the m-TESE (-) group in the testicular volume value at the
right and left scrotal color doppler (Table 3).
3.2. Statistical results according to the ROS (+) and (-)
values
In the ROS (-) group, the m-TESE positivity was
significantly higher and the FSH value was significantly
lower than in the ROS (+) group (p < 0.05). In both the
ROS (-) and ROS (+) groups, no significant difference (p >
0.05) was observed in the m-TESE success rate, Jhs score,
fertilized oocyte count, pregnancy rate, distribution rate of

781

ŞALVARCI et al. / Turk J Med Sci
Table 3. Age, smoking status, FSH values before surgery and chemotherapy, hormonal values before surgery, semen
volumes, testicular volumes, sexual life, and statistical differences between duration of surgery of patients who were
positive/negative at microtesticular sperm extraction.
m-TESE (-)

m-TESE (+)

Mean ± s.s./n-%

Median

Mean ± s.s./n-%

Median

P

Patient’s age

29.6 ± 5.1

29

31.3 ± 4.5

31.5

0.189t

Nonsmoker

30

73.20

17

77.30

0.937x

Smoker

11

26.80

5

22.70

0.937x

Min-max

Median

Min-max

Median

P

Marriage/year

1.6–6.8

3.2

1.4–7.0

3.55

0.937m

m-TESE/min

89.4–120.6

105

64.6–118

99

0.078m

Before CT-FSH

6.5–10.5

8.43

7.4–10.4

9.07

0.873m

Before m-TESE-FSH

11.6–25.0

16.89

13.5–20.5

17.08

0.812m

Intergroups changes
(m-TESE +/-)

P

P

0.046

0.028

Before m-TESE

Mean ± s.s./n-%

Median

Mean ± s.s./n-%

Median

P

LH mIU/mL

8.1–18.5

12.26

8.5–14.9

10.91

0.336m

TT pg/mL

2.8–6.6

4.44

2.7–7.3

4.08

0.579m

PRL ng/mL

6.2–15.4

9

9.75

0.863m

Semen volumes

2.4–4.6

6.3–14.5

3.6

1.7–3.7

2.7

0.007t

4.2–7.8

6.4

0.045m

6.8

0.032m

Right testicular volumes

2.7–7.1

5.5

Left testicular volumes

1.0–10.0

5.3

4.7–8.3

Mann-Whitney U test/x2 Chi-Square test /Fisher exact
m-TESE: Microtesticular sperm extraction. CT: Chemotherapy. FSH: Follicle-stimulating hormone. LH: Luteinizing
hormone. TT: Total testosterone. PRL: Prolactin. ROS: Reactive oxidative stress test.
m

motile and immotile sperms, and <5h time-lapse cleavage
values (Table 4).
3.3. Statistical results according to the SDFI levels of <15
and ≥15
In the group with an SDFI of <15, the m-TESE positivity,
JHS score, and fertilized oocyte count were significantly
higher (p < 0.05) than those in the group with an SDFI of
>15. In the group with an SDFI of <15, the FSH value was
significantly lower (p < 0.05) than that in the group with
an SDFI of ≥15. In the groups with an SDFI of <15 and
an SDFI of ≥15, insignificant differences (p > 0.05) in the
ICSI-total pregnancy rates, motility/nonmotility sperm
distributions, and <5h time lapses were observed (Table 4).
In five patients with an FSH value of <12 mIU/L, a
ROS rate of <1.42 mV/106 sperms/mL, an SDFI rate of
<15, and an embryonic cleavage period of <6 h at the timelapse, fertilization occurred in 4/5 (80%) patients, and the
baby take-home rate was 4/5 (80%) patients, which were
significantly higher than in the general group (p < 0.05).
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In four patients with an FSH value of >25 mIU/L, a ROS
rate of >1.42 mV/106 sperms/mL, an SDFI rate of >25,
and an embryonic cleavage period of >12 h at the timelapse, the fertilization rate was 1/4 (25%) patients, and the
pregnancy rate was 1/4 (25%) patients, but the pregnancy
with an intrauterine ex fetus was terminated. The rates
in this group were significantly lower than those in the
general group (p < 0.05) (Table 4). The Jhs score was >6
in the patients with a low FSH value, a normal ROS rate,
and no sperm detected at the m-TESE. For the patients
with high FSH, ROS, and SDFI rates, the JHS score was
<3. In the group that brought home a child, the sperms of
the patients were motile. The same results were seen in five
patients from whom sperms were obtained at the m-TESE,
whose FSH rate was low, and whose ROS and SDFI rates
were normal (Table 4).
Testicular volumes before and after chemotherapy,
semen analysis, hormone, and reactive oxidative stress
mean values according to cancer diagnosis are shown in
Table 5.

Positive n/%

3.18–5.22

3.45–5.27

Negative n/%

Fertilized oocyts count

Time-lapse < 5h

2/40.0

Motile n/%

Inmotile n/%

3/25.0

4/80.0

1/20.0

4

3

5/41.7

Inmotile n/%

3/25.0

Negative n/%

3.12–5.12

2.03–6.87

3.64–7.94

4.89–11.09

0.7–1.36

7/58.3

Motile n/%

9/75.0

Positive n/%

4.4

4

5

8.96

1.11

x2

0.619
x2

0.099

p

0.690m

0.774
m

0.142m

0.002
m

0.002m

p

Motile n/%
1/20.0

4/80.0

2/40.0

3/60.0
Inmotile n/%

Positive n/%

Negative n/%

4

5

1.0–3.8
3.09–4.87

2

22.35

1.08–4.12
0.9–4.23

17

Median

5.81–10.59

Min-max

SDFI > 15, n = 13

5/38.5

Inmotile n/%

2/15.6

Negative n/%

3.27–4.67

3.27–6.73

2.42–6.88

3.87–24.29

4.19–11.99

Min-max

SDFI < 15, n = 5

8/61.5

Motile n/%

11/84.6

Positive n/%

4

5

4

12.69

8.5

Median

0.818x2

1.00x2

p

0.818m

0.294m

0.046m

0.048m

0.002m

p

m
Mann-Whitney u test/x2 Chi-square test /Fisher exact
m-TESE: Micro-testicular sperm extraction, CT: Chemotherapy, FSH: Follicle-stimulating hormone, ROS: Reactive oxidative stress test, Jhs: Johnson’s score, Time-Lapse:
Embryoscope®, ICSI: Intracytoplasmic sperm injection. Johnsen score of testicular biopsies score morphological base: 1 Tubular sclerosis, 2 Sertoli cells only, 3 Spermatogonia
only, 4 Arrest at primary spermatocyte, no, spermatids, 5 Many spermatocytes, no spermatids, 6 No late spermatids, arrest at spermatid stage, 7 No late spermatids, but many early
spermatids, 8 Few late spermatids, 9 Many late spermatids, disorganized tubular epithelium, 10 Full spermatogenesis.

Sperm motility

ICSI-total pregnancy

4.3

1.63–5.97

Jhs score

25.6

1.63–5.97

FSH mIU/mL

2.44

1.77–3.17

m-TESE(+)

Median

Min-max

Min-max

Median

ROS(-) ,<1.42, n = 12

ROS(+), >1.42, n = 5

Table 4. Evaluation of microtesticular sperm extraction, FSH, pathology, fertilized oocyte count, pregnancy rates, sperm motility/nonmotility, and separation periods at time-lapse
according to the result of the reactive oxidative stress and sperm DNA fragmentation.
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784

42.34 ± 9.89 40.7 ± 8.79

34.67 ± 8.97 32.45 ± 21

8

3

1

4

ALL

AML

CML

Hodgkin’s lymphoma

Non-Hodgkin’ lymphoma 8

Rhabdomyosarcoma

none

1

Wilms tumor

34.5

45.6 ± 2.1

32.12

32.44

-

-

-

0.126m

0.073m

0.146
m

0.001m

3.3

3.1

0.122m

2.8

2

0.000m

0.000m

0.026
m

2.9 ± 0.9 0.000m

2.9 ± 1

4.4 ± 1.2 3.4 ± 2

3.2

3.4 ± 2

3 ± 1.8

m

0.000m

4.4 ± 2.1 3.9 ± 1.7 0.107

4.2
6

P

m

none

23.12 ± 9.87
m

m

7.89

16.78

azospermia 0.001m 4.56 ± 2

0.001

m

9.78 ± 2

0.001m 20.78

21.78 ± 1.8

0.126m

m

0.001m none

1.42

0.001m

-

0.001 1.23 ± 0.22 1.34 ± 0.33 0.001m

1.42 ± 0.34 -

5.68 ± 3.55 0.001 1.11 ± 0.23 2.34 ± 1.2

8.7

7.8 ± 3.70

m

0.001m none

2.78 ± 0.68 0.001 1.45 ± 0.66 1.5 ± 0.34

32.78 ± 12.91 4.8 ± 0.6

22.78 ± 2

m

0.000m

ROS before ROS after
P
CT
CT
0.001m 1.23 ± 0.56 1.77 ± 1.2

TT pg/mL
P
before CT

29.87 ± 12.65 0.001m 11.78 ± 3.95 6.98 ± 3.73 0.001m 0.98 ± 0.22 1.98 ± 0.23 0.001m

azospermia 0.001 7.89 ± 2.3 32 ± 13.27

azospermia

azospermia 0.001 6.57 ± 3.4 18.97 ± 5.67 0.001

azospermia -

m

azospermia 0.001 8.75 ± 3.45 22.34 ± 7.68 0.001
m

TT pg/mL
before CT

0.001m 12.78 ± 2.89 6.8 ± 3.67

FSH IU/
FSH IU/mL
mL before
P
after CT
CT

azospermia 0.001m 7.89 ± 2.45 18.3 ± 4.87

SC/mL
after CT

azospermia -

none

34.2

-

none

none

azospermia -

none

23.67

-

none

23.34 ± 5.67 × 106 azospermia 0.001m 6.78 ± 2.34 15.67 ± 3.78 0.001m none

none

7.68 ± 3.77 -

3.78 ± 1.76 -

4.88 ± 1.75 -

1.76

none

1.14

1.34 ± 0.23 2.0 ± 1.22

none

-

0.000m

-

19.67 ± 3.56 × 106 azospermia 0.001m 6.45 ± 3.2 18.98 ± 4.67 0.001m 12.78 ± 1.96 5.78 ± 2.22 0.001m 1.22 ± 0.23 2.31 ± 0.45 0.000m

17.4 ± 5.46 × 106

18.4 ± 4.56 × 10

none

18.79 ± 4.53 × 10

2.2 ± 0.6 0.001

6 ± 2.4
6

none

m

3.2 ± 1.2 2.3 ± 1.1 0.001m

6

5.8 ± 3.5 × 10

m

3.6 ± 1.1 4.2 ± 1.8 0.126

SC/mL
before CT
7.9 ± 2.5 × 106

SV/mL
P
after CT
3.6 ± 1.9 0.056m

4 ± 1.2

SV/mL
before
CT

m

Mann-Whitney U test
ALL: Acute lymphoblastic leukemia. AML: Acute myelocytic leukemia. CML: Chronic myelocytic leukemia. FSH: Follicle-stimulating hormone. ROS: Reactive oxidative stress test.
CT: Chemotherapy, TT: Total testosterone

none

none

3

Osteosarcoma

44.5 ± 13.4

m

34.56 ± 6.78 0.023m

0.001
m

0.001m

P

26.78 ± 3.45 23.45 ± 4.56 0.037

33.56 ± 22

39.89 ± 11.23 29.78 ± 9.2

Soft tissue Ewing sarcoma 1

2

33.45 ± 12.34 32.56 ± 11

8

39.6 ± 17.7

Nonseminoma

49 ± 22

24

Seminoma

TV/mL
after CT

Num.

Oncologıcal diagnoses

TV/mL
before CT/

Table 5. Testicular volumes before and after chemotherapy, semen analysis, hormone, and reactive oxidative stress mean values according to cancer diagnosis.
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4. Discussion
As stated previously, both cancer and cancer treatments
such as CT, RT, and biologic therapies harm male fertility
by disrupting sperm production. The most frequently used
strategies to address this issue are sperm cryopreservation
and sperm banking before cancer treatment. However,
they are not yet widely used. One reason for this is that
patients are not sufficiently informed about them, as were
our patients [11,12]. In many patients who had undergone
CT due to various types of cancer, sperms may still be
detected in their semen within one to six years after their
CT. However, azoospermia becomes permanent in onethird of cases [11,12]. In a study with participants similar
to those in this study but older, 67 couples aged 24–44 years
who were diagnosed with testicular cancer or lymphoma
received adjuvant treatment with CT and/or RT following
BEP and MOPP treatment. A permanent sperm loss of
57% was noted in the group that did not undergo sperm
freezing, despite having had a child after 82 ICSI and 14
ICSI-frozen embryo replacement procedures [12]. In this
study, persistent azoospermia was found at a higher rate,
in 41/63 (65%) patients. Although the negative impacts
of different chemotherapeutic agents on spermatogenetic
activity have been disclosed, unfortunately, whom among
patients will or will not be impacted is still uncertain
[7, 13]. In the study conducted for this purpose, sperm
freezing was found necessary in the cases of 12 patients
who received BEP/MOPP CT/RT for testicular cancer and
HL. Although sufficient sperms were detected for ICSI in
some patients after treatment, permanent azoospermia
still developed; and even after m-TESE, no sperm could
not be found in some patients [13]. It is recommended
that relevant measures be adopted for fertility as early
as possible before initiating the treatment [7,11,12].
Unfortunately, the patients in our series applied to us when
they already had persistent azoospermia. They recorded
that they had not been sufficiently informed of this topic
and had no frozen sperms. With the advances in m-TESE
and ICSI, the chances of becoming a father after CT have
increased, as observed in our patients and those in other
studies [12,14,15]. In studies of heterogeneous patient
groups with various types of cancer that were conducted in
2003, 2011, and 2016, sperms were detected using m-TESE
in 41.6%, 42.9%, and 37% of the cases, respectively; and
in this study, in 34.9% of the cases [13, 16]. Sperms were
detected at a rate of 47% using m-TESE and a live birth
rate of 27% was achieved in a study similar to ours,
with patients aged 19–49 years who had undergone CT/
RT due to ALL (21 cases), HL (9 cases), AML (7 cases),
NHL (7 cases), rhabdomyosarcoma (7 cases), bladder
cancer (3 cases), and osteosarcoma (2 cases), and who
did not receive relapse treatment and did not undergo
sperm cryopreservation within three years following

RT/CT [16]. The difference between our patients and
those in other studies was that our patients completed
the maintenance and recurrence treatments during their
infertility treatment. In the other studies, most of the
m-TESE procedures were performed during CT or in the
early period after CT (within one to three years) [16]. Our
study had a higher success rate in generating a reservoir
for spermatogenetic activity [14]. There is certainly a
definitive rate of finding sperms after CT. However, the
duration of CT sessions, differences in chemotherapeutic
agents, maintenance doses, and treatment of recurrences
are definitive factors of the success rate of sperm retrieval.
Success rates vary significantly considering the m-TESE
results of individual cancer patients. Therefore, we believe
that the success rates for homogenous groups should be
evaluated separately according to the type of CT and the
maintenance and recurrence treatment. This approach
may be more descriptive before treatment of cancer in
patients who require fertility. Regarding individual factors
of sperm retrieval, the mean age of the patients who
were ontologically diagnosed in our study was 30 years,
whereas the mean age in different studies was ≥35 years
[13,15,16]. The total pregnancy rate was 20.63% and the
baby take-home rate was 12.7% in our study, whereas the
total pregnancy rates in other studies were 50% and 34.8,
and the baby take-home rates were 42% and 27.3% [13].
Various factors, such as different oncological diagnoses,
type of CT administered, maintenance and recurrence
therapies, SDF, high oxidative stress, sperm motility or
nonmotility, the age of the woman, oocyte maturation,
and therefore, embryonic development were considered
in monitoring different rates [13,17]. In a study that
involved 73 patients with NHL, HL, leukemia, testicular
cancer, sarcoma, and neuroblastoma with post-CT
azoospermia, the mean FSH (21.9 mUI/mL), TT (354.4
ng/dL), and testicular volumes (9.1/mL) before m-TESE
were predictive factors both for m-TESE and ICSI, as in
our study [17]. Unlike this study and others, the ROS value
before the m-TESE and the presence of SDFI and motile
sperms in the pregnancies and live births following ICSI
established a different perspective for the patients in our
study.
In our study, the sperm detection rate (50.7%) in
patients who had undergone CT for testicular cancer
was high, as in the other studies (39%–62%) [17,18]. This
was probably because platinum-based therapies were low
gonadotoxic [18,19]. Our sperm detection rate was low
especially in the NHL patients in the lymphoma group
and in the ALL patients. These patients had received
more gonadotoxic alkylating agents [18,19]. In the study
composed of 17 patients, an irreversible azoospermia rate
of 58.8% was detected in our study, where the patients
received an alkylating agent such as cyclophosphamide. It
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had been reported that in the presence of these agents, the
m-TESE success rates were lower [18,19].
Although the Jhs score was detected differently as 2
and 3, sperms were retrieved from the m-TESE. Thus, it
was observed that the spermatogenetic activity maintained
its heterogenicity along all seminiferous channels also in
the chemotherapeutic persistent infertile azoospermia
patients, such as the patients who did not receive cancer
treatment, and that pathology was not important for the
next m-TESE or empirical medical approaches. Therefore,
when performing m-TESE, it is necessary to check
all seminiferous channels, as with other azoospermia
patients. The duration of our m-TESE procedures was the
same as the average of the azoospermia patients who did
not receive CT.
A sperm structure that is high in ROS may lead to a
problem in the sperm count and even in sperm production
and may cause infertility [20]. Oxidative stress reduces
fertilization, pregnancy, and live birth rates [20]. Genital
tract infections, varicocele, spinal cord injury, diabetes,
obesity, tobacco smoking, alcohol use, recreational drug
abuse, ionizing radiation, psychological stress, strenuous
exercise, air pollutants, and chemotherapeutic agents
induce oxidative stress [20]. The high ROS level in our
study was considered a reflection on the ejaculate of
persistence of the permanent tissue damage that probably
developed after CT. Although no other factor affected
ROS microbiologically, we still did not think that it was
an objective indicator of ROS. However, the success of the
m-TESE in our study emerged as a good/bad criterion of
the pregnancy and baby take-home rates. The high FSH
value in the m-TESE (-) group, the low levels of semen
volumes and testicular volumes, and the fact that the same
findings were arrived at in the patients who were ROS (+)
and had an SDFI were accepted as objective findings of the
negative impact of CT. We considered that as the Jhs was
6 in the patients with a normal ROS and FSH and from
whom no sperm was retrieved at the m-TESE, the impact
of CT on testicular tissue was accurately reflected in ROS
and FSH. As a result, although no sperm was retrieved,
there was spermatogenetic activity in the tissue. Almost
no spermatogenetic activity was detected in the pathology
JHS < 4 in the patients who were ROS (+)(>1.42) and had
a high FSH.
The SDFI rate is an important criterion of the potential
for fertility and the pregnancy rate [21]. In unexplainable
fertilization failures, miscarriages, and pregnancy wastages,
the SDFI is checked [21]. We know that the sperms in the
testes have the best SDFI along the ejaculatory duct [22].
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Within this scope, does CT harm sperm DNAs? While
the SDFI rate was low in 13 patients, it was >15–30 in
four patients. The fact that the SDFI was not high in all
the patients showed that CT did not have a completely
negative impact on sperm DNAs. The SDFI rates were
high in patients with a high ROS. The fact that nonmotility
and significant sperm head abnormalities were observed
in patients with a high ROS and SDFI showed that ROS
and SDFI are important criteria before m-TESE and ICSI.
Time-lapse may be utilized to select the embryos
with the highest potential of achieving pregnancy after
monitoring the early and late morphological characteristics
of the embryos as well as the rate and timing of their
development [10]. In multicenter studies, the pregnancy
rate was very low in embryos in which the second cleavage
(tPB2) occurred five h earlier. In our study, the mean period
of the occurrence of the second cleavage was 5 h. In patients
with immotile sperms (i.e. HL, NHL, osteosarcoma, and
seminoma patients), the cleavage periods were >8 h. The
cleavage periods at a time-lapse were prolonged by >12
h especially in patients with a high ROS rate, who were
m-TESE (+), and who had an SDFI of >25. Time-lapse was
an indicator—although subjective—of the negative impact
of CT on the embryo.
Some patients were previously m-TESE (-), but sperms
were retrieved from them after repeat m-TESE. They did
not receive any treatment intended for fertility. Although
the reason for this was not fully understood, possible
reasons are the practical knowledge of the clinic where
the m-TESE was performed, the application of macroTESE instead of m-TESE, and very short surgical periods.
Thus, the administration of a single m-TESE in patients is
insufficient and should be continued for sperm detection.
In conclusion, sperms may be detected using m-TESE
in patients who develop persistent azoospermia associated
with CT due to different oncological diagnoses. Unlike
other studies, our study revealed that a low FSH value
and normal ejaculatory ROS rates are positive predictive
factors of sperm detection before m-TESE. The motility
of the sperms detected after m-TESE and normal SDFI
rates were found to be positive predictive criteria of high
fertilization, good embryonic cleavage, pregnancy, and live
birth.
Acknowledgment/Disclaimers/Conflict of interest
The English in this document has been checked by
professional editors and native speakers of English in
Scribendi. The certificate number in Scribendi is 826995.

ŞALVARCI et al. / Turk J Med Sci
References
1.

Sung H, Ferlay J, Siegel RL, Laversamme M, Soerjomataram
I et al.Global Cancer Statistics 2020: GLOBOCAN Estimates
of Incidence and Mortality Worldwide for 36 Cancers in 185
Countries. CA: A Cancer Journal for Clinicians 2021;71(3):209249. doi: 10.3322/caac.21660

13.

Meseguer M, Garrido N, Remohí J, Pellicer A, Simon C et
al. Testicular sperm extraction (TESE) and ICSI in patients
with permanent azoospermia after chemotherapy. Human
Reproduction 2003;18:1281–1285. doi: 10.1093 /humrep/
deg260

2.

Schover LR, Rybicki LA, Martin BA , Bringelsen KA. Having
children after cancer: A pilot survey of survivors’ attitudes and
experiences. Cancer 1999;86:697-709. doi: 10.1002/(sici)10970142(19990815)86:4<697::aid-cncr20>3.0.co;2-j

14.

Schlegel PN. Testicular sperm extraction: microdissection
improves sperm yield with minimal tissue excision. Human
Reproduction 1999;14:131–135. 10.1093/humrep /14.1.131

15.

3.

Agarwal A, Prabakaran S, Allamaneni SS . Relationship
between oxidative stress, varicocele, and infertility: a metaanalysis. Reproductive Biomedicine Online 2006;12(5):630–
633. doi: 10.1016/s1472-6483(10)61190-x

Palermo G, Joris H, Devroey P, Van Steirtegman AC.
Pregnancies after intracytoplasmic injection of single
spermatozoa into an oocyte. Lancet 1992;340:17–18.
doi: 10.1016/0140-6736(92)92425-f

16.

4.

Bui A, Sharma R, Henkel R, Agarwal A . Reactive oxygen
species impact on sperm DNA and its role in male infertility.
Andrologia 2018; 50(8):e13012. doi: 10.1111/and.13012

5.

Spermon JR, Ramos L, Wetzels AM. Sperm integrity pre-and
post-chemotherapy in men with testicular germ cell cancer.
Human Reproduction 2006;21:1781-1786. doi: 10.1093/
humrep /del084

Shin T, Kobayasahi T, Shimomura Y, Iwahata T, Suzuki K et
al. Microdissection testicular sperm extraction in Japanese
patients with persistent azoospermia after chemotherapy.
International Journal of Clinical Oncology 2016; 21(6): 11671171. doi: 10.1007/s10147-016-0998-5

17.

Hsio W, Stahl P, Osterberg EC, Nejat E, Palermo GD et al.
Successful treatment of post-chemotherapy azoospermia with
microsurgical sperm extraction: the Weill Cornell experience.
Journal of Clinical Oncology 2011; 20: 1607-11. doi: 10.1200/
JCO.2010. 33 .7808

18.

Meistrich ML, Wilson G, Brown BW, Cunha MF . Impact
of cyclophosphamide on long-term reduction in sperm
count in men treated with combination chemotherapy
for Ewing and soft tissue sarcomas. Cancer 1992;70:27032712. doi: 10.1002/1097-0142(19921201)70 :11<2703::aidcncr2820701123>3.0.co;2-x

19.

Kenney LB, Laufer MR, Grant FD, Grier H, Diller L.
High risk of infertility and long-term gonadal damage
in males treated with high dose cyclophosphamide for
sarcoma during childhood. Cancer 2001;91:613-621.
doi: 10.1002/1097-0142(20010201)91:3<613::aid-cncr1042>
3.0.co;2-r

20.

Agarwal A, Buid AD. Oxidation-reduction potential as a new
marker for oxidative stress: Correlation to male infertility.
Investigative and Clinical Urology 2017;58(6):385-399.
doi: 10.4111/icu. 2017.58.6.385

21.

Practice Committee of the American Society for Reproductive
Medicine. Diagnostic evaluation of the infertile male: a
committee opinion. Fertility and Sterility 2015;103:e18–25.
doi: 10.1016/j.fertnstert.2015.03.019

22.

Moskovtsev SI, Jarvi K, Mullen JB, Cadesky KI, Hannam T
et al. Testicular spermatozoa have statistically significantly
lower DNA damage compared with ejaculated spermatozoa
in patients with unsuccessful oral antioxidant treatment.
Fertility and Sterility 2010; 93: 1142–1. doi: 10.1016/j.
fertnstert.2008.11.005

6.

Shin T, Miyata A, Arai G, Okada H. Fertility in testicular
cancer patients (in Japanese). Gan To Kagaku Ryoho (Japanese
Journal of Cancer and Chemotherapy) 2015;42:267–271

7.

Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J et al.
Fertility Preservation in Patients with Cancer: ASCO Clinical
Practice Guideline Update. Journal of Clinical Oncology 2018;
36(19):1994-2001. doi: 10.1200/JCO.2018.78.1914

8.

Gorczyca W, Gong J, Darzynkiewicz Z. Detection of DNA
strand breaks in individual apoptotic cells by the in situ
terminal deoxynucleotidyl transferase and nick translation
assays. Cancer Research 1993; 53: 1945-51

9.

Agarwal A, Roychoudhury S, Sharma R, Gupta S,
Majzoub A et al. Diagnostic application of oxidationreduction potential assay for measurement of oxidative
stress: clinical utility in male factor infertility. Reproductive
Biomedicine Online 2017;34(1):48-57. doi: 10.1016/j.rbmo.
2016. 10.008

10.

Salvarci A, Gurbuz AS, Uzman S, Kaya M, Gorkemli
H. Comparison of embryo morphokinetics following
intracytoplasmic sperm injection in smoker and non-smoker
couples: Are the results different? Journal of the Pakistan
Medical Association 2017;67(10):1552-1557

11.

Sigman M. Cancer treatment and male infertility: effects
of therapy and current and future management options.
Fertility and Sterility 2013; 100:11791186. doi: 10.1016/
j.fertnstert.2013.09.011

12.

Schmidt KL, Larsen E, Bangsboll S, Meinertz H, Carlsen E et
al. Assisted reproduction in male cancer survivors: Fertility
treatment and outcome in 67 couples. Human Reproduction
2004;19:2806-2810. doi: 10.1093/humrep/deh518

787

